Evidence map›Paper›PMID 42368860›Full record

ReviewFrontiers in cardiovascular medicine2026

Preoperative cardiovascular evaluation in patients with cancer.

Carl Zehner, Noah I Beinart, Jung Hyun Kim, Andrea Ruesta Carrion, Angelica Paniagua-Bojorges, Silvia Fernanda López Moreno, Bernardo Casso-Chapa, Keila Ostos Mendoza, Venkata Subrahmanya Kumar Samanthapudi, Jonghae Lee and 11 more

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Carl Zehner *Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Noah I Beinart *Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jung Hyun Kim *Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Andrea Ruesta CarrionDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Angelica Paniagua-BojorgesDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Silvia Fernanda López MorenoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Bernardo Casso-ChapaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keila Ostos MendozaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Venkata Subrahmanya Kumar SamanthapudiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jonghae LeeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Kun Yuan ChuDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Oanh HoangDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Gilbert F MejiaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Anita DeswalDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nicolas L PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sivareddy KotlaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nhat-Tu LeDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Efstratios KoutroumpakisDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Syed Wamique YusufDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jun-Ichi AbeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Michael S EwerDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer patients undergoing non-cardiac surgery represent a uniquely high-risk group for perioperative cardiovascular complications. These individuals frequently exhibit coronary artery disease, peripheral arterial disease, cardiomyopathy, valvular dysfunction, arrhythmias, pericardial disease, and heightened thrombotic or bleeding risk. Many surgeries in this population are time-sensitive rather than elective, limiting opportunities for optimization and requiring clinicians to balance competing risks. Current guidelines provide limited oncology-specific recommendations; however, several strategies can improve outcomes. These include incorporating cancer history into risk stratification, lowering thresholds for transthoracic echocardiography (TTE) and BNP screening in patients at risk for cancer therapy-related cardiac dysfunction (CTRCD), performing ECG in those at risk for QTc prolongation, and extending thromboprophylaxis for 4-5 weeks after major surgery. Multidisciplinary collaboration remains essential. Preoperative evaluation should integrate patient- and procedure-related risks, avoiding unnecessary testing in low-risk surgeries or patients with good functional capacity. Functional capacity assessment using METs or validated tools such as the Duke Activity Status Index (DASI), ECG, biomarkers, and surgical risk calculators (e.g., RCRI, ACS NSQIP) guide decision-making. Coronary revascularization should follow standard indications, such as significant left main or multivessel disease, rather than routine prophylactic intervention, as demonstrated by trials like CARP and reinforced by registry data in high-risk anatomy. Antithrombotic management, including continuation of aspirin, selective use of dual antiplatelet therapy, and bridging strategies with cangrelor or heparin in high-risk patients, further influences perioperative outcomes. By combining guideline-directed care with oncology-specific considerations, clinicians can optimize surgical safety and reduce cardiovascular complications.

Indexed as

cancer patientscardio-oncologymultidisciplinary collaborationpreoperative evaluationrisk stratificationthromboprophylaxis

Identifiers

PMID42368860
PMCPMC13307110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.